Show simple item record

dc.contributor.authorDiro, Ermiasen
dc.contributor.authorGriensven, Johan vanen
dc.contributor.authorWoldegebreal, Tekluen
dc.contributor.authorBelew, Zewduen
dc.contributor.authorTaye, Meleseen
dc.contributor.authorYifru, Sisayen
dc.contributor.authorDavidson, Robert N.en
dc.contributor.authorBalasegaram, Manicaen
dc.contributor.authorLynen, Luten
dc.contributor.authorBoelaert, Marleenen
dc.date.accessioned2018-07-31T13:52:05Z
dc.date.available2018-07-31T13:52:05Z
dc.date.issued2018-07
dc.identifier.urihttp://hdl.handle.net/10144/619248
dc.descriptionResearch Protocolen
dc.description.abstract2.1 OBJECTIVES 2.1.1 General objective: To document the effectiveness, safety and feasibility of monthly PM secondary prophylaxis (PSP) in VL/HIV co-infected patients that have documented parasite clearance after VL treatment when used for prevention of VL relapse. 2.1.2 Specific objectives of the primary study period 2.1.2.1 Primary objectives In VL/HIV co-infected patients that have documented parasite clearance after VL treatment: - to assess the effectiveness of PSP in terms of preventing relapse and death; - to assess the safety of PSP in terms of drug-related serious adverse events or permanent drug discontinuations due to adverse events; - to assess the feasibility of PSP in terms of number of patients compliant to therapy during the first year of monthly PM secondary prophylaxis. 2.1.2.2 Secondary objectives; In VL/HIV co-infected patients that have documented parasite clearance after VL treatment: - to assess the safety of PSP in terms of: - drug-related non-serious adverse events - serious adverse events (drug-related or not) - to assess the feasibility of PSP in terms of: - number of treatment interruptions/discontinuations, - number of therapeutic interventions needed to treat adverse drug reactions
dc.language.isoenen
dc.rightsThese materials can be used, adapted and copied as long as citation of the source is given including the direct URL to the material. This work is licensed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0/ https://i.creativecommons.org/l/by/4.0/88x31.pngen
dc.subjectSecondary prophylaxisen
dc.subjectvisceral leishmaniasis relapsesen
dc.subjectHIVen
dc.subjectpentamidineen
dc.subjectprophylactic agenten
dc.subjectcohort studyen
dc.titleSecondary prophylaxis of visceral leishmaniasis relapses in HIV co-infected patients using pentamidine as a prophylactic agent: a prospective cohort studyen
dc.typeOtheren
dc.contributor.departmentMSF-OCAen
refterms.dateFOA2019-02-21T13:44:58Z
html.description.abstract2.1 OBJECTIVES 2.1.1 General objective: To document the effectiveness, safety and feasibility of monthly PM secondary prophylaxis (PSP) in VL/HIV co-infected patients that have documented parasite clearance after VL treatment when used for prevention of VL relapse. 2.1.2 Specific objectives of the primary study period 2.1.2.1 Primary objectives In VL/HIV co-infected patients that have documented parasite clearance after VL treatment: - to assess the effectiveness of PSP in terms of preventing relapse and death; - to assess the safety of PSP in terms of drug-related serious adverse events or permanent drug discontinuations due to adverse events; - to assess the feasibility of PSP in terms of number of patients compliant to therapy during the first year of monthly PM secondary prophylaxis. 2.1.2.2 Secondary objectives; In VL/HIV co-infected patients that have documented parasite clearance after VL treatment: - to assess the safety of PSP in terms of: - drug-related non-serious adverse events - serious adverse events (drug-related or not) - to assess the feasibility of PSP in terms of: - number of treatment interruptions/discontinuations, - number of therapeutic interventions needed to treat adverse drug reactions


Files in this item

Thumbnail
Name:
Final_protocol_secondary_proph ...
Size:
568.1Kb
Format:
Microsoft Word 2007
Description:
Research Protocol

This item appears in the following Collection(s)

Show simple item record